Skip to main content

Table 3 The comparison of clinical parameters at baseline

From: Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?

  RLDA (n = 27) MHDA (n = 37) p value
Age (years) 56.3 ± 15.7 59.9 ± 12.1 0.334
Female/male 18/9 31/6 0.110
Disease duration (years) 10.3 ± 8.3 15.1 ± 13.6 0.082
PSL dose (mg/day) 2.2 ± 2.5 1.8 ± 2.1 0.483
MTX dose (mg/week) 5.2 ± 3.4 6.1 ± 3.6 0.321
ESR (mm/h) 53.1 ± 33.9 68.9 ± 29.5 0.056
CRP (mg/dL)a 1.7 (0.4–3.1) 1.3 (0.6–2.9) 0.807
WBC (/μL) 7429.6 ± 2078.1 5886.5 ± 2150.2 0.005
% neutrophils 68.3 ± 9.2 69.0 ± 9.3 0.775
% eosinophils 2.0 ± 1.1 2.6 ± 2.8 0.418
% basophils 0.4 ± 0.2 0.4 ± 0.2 0.699
% monocytes 5.9 ± 1.6 4.9 ± 1.9 0.035
% lymphocytes 22.4 ± 7.9 22.0 ± 7.3 0.857
MMP-3 (ng/mL)a 158.0 (95.0–399.3) 134.5 (69.1–500.0) 0.579
ACPA (U/mL)a 61.4 (10.7–100.0) 99.1 (15.1–100.0) 0.393
ACPA ≥ 60 U/mL, n (%) 13 (50.0) 21 (58.3) 0.515
RF (U/mL)a 33 (10–100) 61.5 (23.8–211.8) 0.082
RF ≥ 40 U/mL, n (%) 12 (48.0) 22 (64.7) 0.199
DAS28-ESR 4.5 ± 1.4 5.3 ± 1.0 0.008
  1. The data are expressed as the mean ± standard deviation, with the exception of skewed variables (a), which are represented as medians (interquartile range)
  2. RLDA remission and low disease activity; MHDA moderate and high disease activity; PSL prednisolone; MTX methotrexate; ESR erythrocyte sedimentation rate; CRP C-reactive protein; WBC white blood cell count; MMP-3 matrix metalloproteinase-3; ACPA anti-cyclic citrullinated peptide antibody; RF rheumatoid factor; DAS28 Disease Activity Score in 28 joints